During the last session, NewAmsterdam Pharma Company NV (NASDAQ:NAMS)’s traded shares were 0.59 million, with the beta value of the company hitting -0.03. At the end of the trading day, the stock’s price was $25.94, reflecting an intraday loss of -0.08% or -$0.02. The 52-week high for the NAMS share is $27.29, that puts it down -5.2 from that peak though still a striking 55.4% gain since the share price plummeted to a 52-week low of $11.57. The company’s market capitalization is $2.77B, and the average intraday trading volume over the past 10 days was 0.61 million shares, and the average trade volume was 752.61K shares over the past three months.
NewAmsterdam Pharma Company NV (NAMS) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. NAMS has a Sell rating from 0 analyst(s) out of 1 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it.
NewAmsterdam Pharma Company NV (NASDAQ:NAMS) trade information
NewAmsterdam Pharma Company NV (NAMS) registered a -0.08% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -0.08% in intraday trading to $25.94, hitting a weekly high. The stock’s 5-day price performance is -1.11%, and it has moved by 29.83% in 30 days. Based on these gigs, the overall price performance for the year is 114.91%. The short interest in NewAmsterdam Pharma Company NV (NASDAQ:NAMS) is 2.58 million shares and it means that shorts have 1.88 day(s) to cover.
The consensus price target of analysts on Wall Street is $41, which implies an increase of 36.73% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $36 and $48 respectively. As a result, NAMS is trading at a discount of -85.04% off the target high and -38.78% off the low.
NewAmsterdam Pharma Company NV (NAMS) estimates and forecasts
Statistics show that NewAmsterdam Pharma Company NV has underperformed its competitors in share price, compared to the industry in which it operates. NewAmsterdam Pharma Company NV (NAMS) shares have gone up 29.70% during the last six months, with a year-to-date growth rate less than the industry average at 4.19% against 16.60.
While earnings are projected to return 5.04% in 2025.
NAMS Dividends
NewAmsterdam Pharma Company NV is due to release its next quarterly earnings in February. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
NewAmsterdam Pharma Company NV (NASDAQ:NAMS)’s Major holders
NewAmsterdam Pharma Company NV insiders own 0.22% of total outstanding shares while institutional holders control 79.93%, with the float percentage being 80.10%.
